STERIS plc provided revenue guidance for fiscal 2023. For fiscal 2023, constant currency organic revenue growth is now anticipated to be approximately 10%, compared with prior expectations of 11%, reflecting ongoing supply chain challenges and procedure volumes somewhat lighter than anticipated. As reported revenue is expected to increase approximately 9%, reflecting the net impact of acquisitions and divestitures as well as approximately $100 million in anticipated negative impact of foreign currency fluctuations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
235.5 USD | -0.23% | +12.08% | +7.10% |
May. 10 | Wolfe Research Adjusts Price Target on STERIS to $240 From $235 | MT |
May. 10 | Piper Sandler Adjusts Price Target on STERIS to $225 From $220 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.10% | 23.32B | |
-4.98% | 181B | |
+2.84% | 112B | |
-2.68% | 67.92B | |
+4.53% | 50.1B | |
+8.00% | 44.27B | |
+9.39% | 40.41B | |
+25.30% | 31.95B | |
-0.17% | 25.82B | |
+17.27% | 25.29B |
- Stock Market
- Equities
- STE Stock
- News STERIS plc
- STERIS plc Provides Revenue Guidance for Fiscal 2023